BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nagaraju GP, Zakka KM, Landry JC, Shaib WL, Lesinski GB, El-Rayes BF. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. Int J Cancer 2019;145:1529-37. [PMID: 30801702 DOI: 10.1002/ijc.32227] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Ashrafizadeh M, Najafi M, Ang HL, Moghadam ER, Mahabady MK, Zabolian A, Jafaripour L, Bejandi AK, Hushmandi K, Saleki H, Zarrabi A, Kumar AP. PTEN, a Barrier for Proliferation and Metastasis of Gastric Cancer Cells: From Molecular Pathways to Targeting and Regulation. Biomedicines 2020;8:E264. [PMID: 32756305 DOI: 10.3390/biomedicines8080264] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
2 Zhu F, Dai SN, Xu DL, Hou CQ, Liu TT, Chen QY, Wu JL, Miao Y. EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathway and EMT. Biomed Pharmacother 2020;125:109972. [PMID: 32036221 DOI: 10.1016/j.biopha.2020.109972] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
3 Tan Z, Xu J, Zhang B, Shi S, Yu X, Liang C. Hypoxia: a barricade to conquer the pancreatic cancer. Cell Mol Life Sci 2020;77:3077-83. [PMID: 31907561 DOI: 10.1007/s00018-019-03444-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
4 Ernst A, Hennel R, Krombach J, Kapfhammer H, Brix N, Zuchtriegel G, Uhl B, Reichel CA, Frey B, Gaipl US, Winssinger N, Shirasawa S, Sasazuki T, Sperandio M, Belka C, Lauber K. Priming of Anti-tumor Immune Mechanisms by Radiotherapy Is Augmented by Inhibition of Heat Shock Protein 90. Front Oncol 2020;10:1668. [PMID: 32984042 DOI: 10.3389/fonc.2020.01668] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kozal K, Jóźwiak P, Krześlak A. Contemporary Perspectives on the Warburg Effect Inhibition in Cancer Therapy. Cancer Control 2021;28:10732748211041243. [PMID: 34554006 DOI: 10.1177/10732748211041243] [Reference Citation Analysis]
6 Gulla A, Kazlauskas E, Liang H, Strupas K, Petrauskas V, Matulis D, Eshleman JR. Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures. Pancreas 2021;50:625-32. [PMID: 33939678 DOI: 10.1097/MPA.0000000000001807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Yun CW, Kim HJ, Lim JH, Lee SH. Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy. Cells 2019;9:E60. [PMID: 31878360 DOI: 10.3390/cells9010060] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
8 Liu Y, Wu L, Lu H, Wu E, Ni J, Zhou X. Enhancing the Therapeutic Efficacy of KRASG12C Inhibitors in Lung Adenocarcinoma Cell Models by Cotargeting the MAPK Pathway or HSP90. J Oncol 2021;2021:2721466. [PMID: 34858498 DOI: 10.1155/2021/2721466] [Reference Citation Analysis]
9 Jin X, Dai L, Ma Y, Wang J, Liu Z. Implications of HIF-1α in the tumorigenesis and progression of pancreatic cancer. Cancer Cell Int 2020;20:273. [PMID: 32587480 DOI: 10.1186/s12935-020-01370-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
10 Yu S, Zhang C, Xie KP. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. Biochim Biophys Acta Rev Cancer 2021;1875:188461. [PMID: 33157162 DOI: 10.1016/j.bbcan.2020.188461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hu LP, Zhou KX, Huo YM, Liu DJ, Li Q, Yang MW, Huang PQ, Xu CJ, Tian GA, Yao LL, Zhang XL, Wang YH, Li J, Zhang ZG, Jiang SH, Xing X, Wang X, Qin WT, Yang Q. Single-cell RNA sequencing reveals that targeting HSP90 suppresses PDAC progression by restraining mitochondrial bioenergetics. Oncogenesis 2021;10:22. [PMID: 33658487 DOI: 10.1038/s41389-021-00311-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Chai Z, Wang L, Zheng Y, Liang N, Wang X, Zheng Y, Zhang Z, Zhao C, Zhu T, Liu C. PADI3 plays an antitumor role via the Hsp90/CKS1 pathway in colon cancer. Cancer Cell Int 2019;19:277. [PMID: 31708688 DOI: 10.1186/s12935-019-0999-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
13 Grbovic-Huezo O, Pitter KL, Lecomte N, Saglimbeni J, Askan G, Holm M, Melchor JP, Chandwani R, Joshi S, Haglund C, Iacobuzio-Donahue CA, Chiosis G, Tammela T, Leach SD. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Proc Natl Acad Sci U S A 2020;117:30670-8. [PMID: 33199632 DOI: 10.1073/pnas.1920240117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Baghery Saghchy Khorasani A, Pourbagheri-Sigaroodi A, Pirsalehi A, Safaroghli-Azar A, Zali MR, Bashash D. The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions. Eur J Pharmacol 2021;898:173983. [PMID: 33647255 DOI: 10.1016/j.ejphar.2021.173983] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Alonso-González C, González A, Menéndez-Menéndez J, Martínez-Campa C, Cos S. Melatonin as a Radio-Sensitizer in Cancer. Biomedicines 2020;8:E247. [PMID: 32726912 DOI: 10.3390/biomedicines8080247] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
16 Peisl S, Mellenthin C, Vignot L, Gonelle-Gispert C, Bühler L, Egger B. Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature. PLoS One 2021;16:e0252397. [PMID: 34138876 DOI: 10.1371/journal.pone.0252397] [Reference Citation Analysis]
17 Wu Q, Zhang H, Sun S, Wang L, Sun S. Extracellular vesicles and immunogenic stress in cancer. Cell Death Dis 2021;12:894. [PMID: 34599143 DOI: 10.1038/s41419-021-04171-z] [Reference Citation Analysis]
18 Bao X, Zhang J, Huang G, Yan J, Xu C, Dou Z, Sun C, Zhang H. The crosstalk between HIFs and mitochondrial dysfunctions in cancer development. Cell Death Dis 2021;12:215. [PMID: 33637686 DOI: 10.1038/s41419-021-03505-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Shah VM, Sheppard BC, Sears RC, Alani AW. Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer. Cancer Lett. 2020;492:63-70. [PMID: 32822815 DOI: 10.1016/j.canlet.2020.07.041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
20 Tao J, Yang G, Zhou W, Qiu J, Chen G, Luo W, Zhao F, You L, Zheng L, Zhang T, Zhao Y. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol 2021;14:14. [PMID: 33436044 DOI: 10.1186/s13045-020-01030-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
21 Srivani G, Behera SK, Dariya B, Chalikonda G, Alam A, Nagaraju GP. HIF-1α and RKIP: a computational approach for pancreatic cancer therapy. Mol Cell Biochem 2020;472:95-103. [PMID: 32562168 DOI: 10.1007/s11010-020-03788-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]